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Abstract
Malignant cells often demonstrate a proliferative advantage when compared to non-malignant cells. However, the rapid 
growth and metabolism required for survival can also highlight vulnerabilities specific to these malignant cells. One such 
vulnerability exhibited by cancer is an increased demand for amino acids (AAs), which often results in a dependency on 
exogenous sources of AAs or requires upregulation of de novo synthesis. These metabolic alterations can be exploited by 
therapy, which aims to improve treatment outcome and decrease relapse and reoccurrence. One clinically utilised strategy 
targeting AA dependency is the use of asparaginase in the treatment of acute lymphoblastic leukaemia (ALL), which results 
in a depletion of exogenous asparagine and subsequent cancer cell death. Examples of other successful strategies include the 
exploitation of arginine deiminase and methioninase, nutrient restriction of methionine and the inhibition of glutaminase. In 
this review, we summarise these treatment strategies into three promising avenues: AA restriction, enzymatic depletion and 
inhibition of metabolism. This review provides an insight into the complexity of metabolism in cancer, whilst highlighting 
these three current research avenues that have support in both preclinical and clinical settings.
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Abbreviations
AA  Amino acid
ALL  Acute lymphoblastic leukaemia
ALT  Alanine aminotransferase
AML  Acute myeloid leukaemia
BCAA  Branched chain amino acid
BCAT  Branched chain aminotransferase
NEAA  Non-essential amino acid
NSCLC  Non-small cell lung carcinoma
PDAC  Pancreatic ductal adenocarcinoma
PDOX  Patient-derived orthotopic xenograft
SCLC  Small-cell lung cancer
Introduction
Cancer is a disease at the cellular level that results from 
oncogenic mutations that lead to altered cellular metabolism, 
promoting tumorigenesis (Pavlova and Thompson 2016). 
Malignant cells often demonstrate characteristic changes in 
their metabolism including increased rates of glutaminolysis 
and fatty acid synthesis, in addition to an increased uptake 
of glucose (Fadaka et al. 2017). These metabolic changes 
can expose vulnerabilities which are specific to malignant 
cells, such as an increased metabolic demand and inefficient 
adenosine triphosphate generation (Vettore et al. 2019). Lit-
erature is now highlighting the importance of AAs as metab-
olites and metabolic regulators in supporting oncogenesis, 
despite their primary role in protein synthesis (Ananieva 
and Wilkinson 2018; Li and Zhang 2016). Due to increased 
metabolic demands, an abundant supply of nutrients such 
as glucose and AAs are important for cancer cells to sus-
tain their proliferative drive (Vettore et al. 2019). There-
fore, nutrient deprivation strategies have been proposed as 
an alternative therapy for cancer treatment.
An increased rate of glycolysis, and therefore glucose 
consumption, is exhibited by many malignant cells and is 
referred to as the Warburg effect (Fig. 1; Warburg 1956), 
highlighting glucose consumption as a potential target for 
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therapeutic intervention. However, glucose restriction leads 
to systemic toxicity due to the effects of deprivation on non-
malignant cells (Jeon et al. 2016). Unlike glucose, the ability 
to synthesise non-essential amino acids (NEAAs) de novo is 
commonly maintained in non-malignant cells yet is lost in 
malignancy. This ensures non-malignant cells are unaffected 
by specific AA restrictions, resulting in the emergence of 
AA restriction as a viable therapeutic strategy. Like glucose, 
there are major differences in the uptake and metabolism of 
several AAs in malignant versus non-malignant cells (Jain 
et al. 2012). It is believed that AAs, rather than glucose, 
account for the majority of the carbon biomass in proliferat-
ing cells, highlighting a significant demand for AAs (Hosios 
et al. 2016).
Amino acid restriction has already proven to be clini-
cally effective in the treatment of ALL, with the use of 
asparaginase. Asparaginase is a bacterial derived enzyme 
that depletes serum levels of the NEAA, asparagine. 
Asparaginase represents one of the first examples of a 
therapeutic approach targeting AA metabolism by exploit-
ing AA auxotrophy in cancer, and has resulted in notable 
improvement of paediatric ALL outcomes. Asparaginase 
treatment is one of the most successful metabolism-target-
ing therapies to date, and its success has prompted further 
studies looking into the effects of exploiting AA metabo-
lism in malignant cells (Vettore et al. 2019). A number 
of strategies have been proposed to exploit AA metabo-
lism and the increased demand for nutrients in malignant 
cells. These strategies include dietary restriction of AAs, 
enzymatic depletion of exogenous AAs and inhibition of 
enzymatic AA metabolism. All of these methods highlight 
specific vulnerabilities and potential avenues for cancer 
therapy. This review will summarise key studies relat-
ing to the targeting of AA metabolism in cancer therapy; 
including ALL, melanoma and hepatocellular carcinoma 
(Table 1).
Fig. 1  A representation of the differences between oxidative phos-
phorylation, anaerobic glycolysis and aerobic glycolysis (Warburg 
effect). In the presence of oxygen, healthy cells metabolise glucose to 
pyruvate via glycolysis. Pyruvate is oxidised within the mitochondria 
to produce  CO2 during oxidative phosphorylation. In the absence of 
oxygen, cells generate lactate from pyruvate. This allows glycolysis 
to continue with reduced ATP production in comparison to oxida-
tive phosphorylation. Alternatively, malignant cells undergo aerobic 
glycolysis regardless of oxygen status. Whilst mitochondria remain 
functional, minimal oxidative phosphorylation can take place. Abbre-
viations: ATP adenosine triphosphate; Complex I-IV mitochondrial 
respiratory chain complexes I-IV; mtDNA mitochondrial DNA; PDH 
pyruvate dehydrogenase; ROS reactive oxygen species; TCA tricarbo-
xylic acid. Adapted in Biorender from Vander Heiden et  al. (2009); 
Kim and Dang (2006)
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Enzymatic depletion of amino acids
Treatment consisting of AA metabolising enzymes has clini-
cally demonstrated anti-proliferative efficacy against cancer, 
notably ALL. Non-malignant cells have an innate ability to 
synthesise NEAAs, yet malignant cells often have underly-
ing genetic mutations that result in a loss of this ability. 
This results in many cancers becoming auxotrophic for cer-
tain NEAAs and therefore tumours must rely on exogenous 
sources of these AAs for growth and survival (Vettore et al. 
2019). In the example of ALL, one of the hallmarks of the 
disease is a lymphoblast deficiency in asparagine synthetase. 
High rates of protein synthesis and a poor ability to syn-
thesise asparagine drives ALL lymphoblasts into becom-
ing dependent on the extracellular availability of asparagine 
(Chiu et al. 2019).
Administration of asparaginase catalyses the hydrolysis 
of asparagine in the serum to aspartate and ammonia, result-
ing in decreased serum asparagine levels and growth inhi-
bition or death of leukemic cells (Cachumba et al. 2016). 
Table 1  Summary of key evidence identified in this review
The table contains key treatment mechanisms defined into the three potential avenues of targeting AA metabolism for cancer treatment; enzy-
matic depletion, nutritional restriction and enzymatic inhibition. The table details both preclinical and clinical evidence in addition to the experi-
mental model type used, whilst summarising the key data in support of targeting AA metabolism in cancer
AA amino acid; ALL acute lymphoblastic leukaemia; ALT alanine aminotransferase; BCAAs branched chain amino acids; MSUD maple syrup 
urine disease; NSCLC non-small cell lung carcinoma
Treatment mechanism Model type Preclinical/clinical evidence References
Enzymatic depletion
 Asparaginase Clinical use in ALL Mortality rates in patients aged 
0–24 years have progressively 
decreased by 82% from 1971 to 2016 
since the introduction of asparaginase
Cancer Research UK (2018)
 Arginine deiminase Human metastatic melanoma clinical 
trials
Phase 2 clinical trials predicted an 
increase in median survival of 
8 months (7 vs 15 months) in stage IV 
metastatic melanoma patients
Ascierto et al. (2005)
 Recombinant methioninase Pancreatic cancer and melanoma 
patient-derived orthotopic xenograft 
nude-mouse models
When treated with methioninase, mice 
demonstrated a reduced tumour 
volume in both pancreatic (694 vs 201 
 mm2) and melanoma (3755 vs 858 
 mm2) cancer models
Kawaguchi et al. (2018)
Nutritional restriction
 Branched chain amino acids Clinical use in MSUD Potential activity against cancers that 
are dependent on BCAAs, yet evi-
dence of its efficacy is lacking
N/A
 Methionine Azoxymethane-induced colon carcino-
genesis male F344 rat model
A methionine restricted diet resulted in 
a reduction of colonic cell prolifera-
tion by 12% compared to controls and 
reduced preneoplastic aberrant crypt 
foci
Komninou et al. (2006)
 Ketogenic diet Luciferase-tagged VM-M3 mouse mod-
els of metastatic cancer
The ketogenic diet was associated with a 
reduced tumour growth and increased 
mean survival (31.2 vs 48.9 days)
Poff et al. (2013)
Enzymatic inhibition
 Alanine aminotransferase 2 ALT2 knockdown in human NSCLC 
cell lines
Approximately a 40% reduction in rela-
tive cell density in ALT2 knockdown 
NSCLC cells compared to wildtype
Hodakoski et al. (2019)
 Gabapentin Human glioma cell lines Approximately, a 56% concentration-
dependent reduction in glioma prolif-
eration when treated with gabapentin
Tönjes et al. (2013)
 CB-839 (Telaglenastat) Human advanced or metastatic renal cell 
carcinoma clinical trials
A phase 2 clinical trial demonstrated 
an increase in median progression 
free survival of 1.9 months (3.8 
vs 1.9 months) when treated with 
everolimus and CB-839 compared to 
the control
Motzer et al. (2019)
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The ability of non-malignant cells to continue to synthesise 
asparagine allows the resulting low levels of serum aspara-
gine to disrupt leukemic cell viability without disturbing 
non-malignant cells (Ali et al. 2016). Since the introduc-
tion of asparaginase in the 1960s for the treatment of ALL, 
mortality rates in patients aged 0–24 years has progres-
sively decreased by 82% between 1971 and 2016 (Cancer 
Research UK 2018). The success of asparaginase therapy 
has prompted the development of additional therapeutics 
designed to exploit cancer AA dependencies. These met-
abolic dependencies are described in many cancers, with 
common deficiencies observed in argininosuccinate syn-
thetase (Patil et al. 2016), and glutamine synthetase (Bolzoni 
et al. 2016; Chiu et al. 2019; Furusawa et al. 2018).
Arginine auxotrophy has been successfully exploited uti-
lising the microbial derived enzyme, arginine deiminase, 
which catalyses the conversion of arginine to its precursor 
citrulline. Clinical trials of arginine deiminase in humans 
have demonstrated efficacy in both hepatocellular carci-
nomas and melanomas (Ascierto et al. 2005; Glazer et al. 
2010). Initial studies demonstrated a significant reduc-
tion in serum arginine levels following arginine deiminase 
treatment, associated with an increased median survival of 
8 months in metastatic melanoma patients compared to con-
trols (Ascierto et al. 2005). Comparatively, advanced hepa-
tocellular carcinoma patients exhibited an overall median 
survival of 11.4 months (vs 10.7 months), demonstrating 
an increased efficacy compared to the first-line treatment, 
sorafenib (Glazer et al. 2010; Llovet et al. 2008).
Recently, arginine deiminase has demonstrated efficacy 
in a number of alternative cancers including small-cell lung 
cancer (SCLC) and acute myeloid leukaemia (AML). Kelly 
et al. (2012) demonstrated that SCLC cells frequently lack 
expression of argininosuccinate synthetase and treatment 
with arginine deiminase induced metabolic stress and subse-
quent autophagy, which progressed to apoptosis in up to 16% 
of cancer cells. In addition, arginine deiminase treatment in 
SCLC xenograft mouse models induced a significant dose-
dependent reduction in tumour growth compared to controls. 
Miraki-Moud et al. (2015) demonstrated similar results in 
AML cells in vivo, finding that arginine deprivation induced 
by arginine deiminase significantly reduced the percentage 
of AML cells by more than 50% in the bone marrow of 
mouse models. Utilising the same models, arginine deimi-
nase in combination with the chemotherapeutic agent cytara-
bine (commonly used to treat AML) demonstrated improved 
efficacy than cytarabine alone (Miraki-Moud et al. 2015).
Another example supported by recent evidence is the 
enzymatic depletion of the essential AA, methionine. 
Cancer cell proliferation appears dependent on exogenous 
methionine and is known as methionine dependence or the 
Hoffman effect (Hoffman 2015; Kaiser 2020). Hoffman and 
Erbe (1976) demonstrated that malignant cells were able 
to synthesise high levels of methionine endogenously, yet 
still insufficient levels to maintain cancer growth. Stern 
and Hoffman (1984) noted that an overall increase in trans-
methylation reactions within malignant cells is likely the 
basis of this methionine-dependence. This alteration within 
malignant cells has resulted in methionine addiction being 
recognised as a fundamental hallmark of cancer and onco-
genic transformation (Booher et al. 2012; Chello and Bertino 
1973; Coalson et al. 1982; Halpern et al. 1974; Hoffman 
2015; Hoffman and Erbe 1976; Hoffman and Jacobsen 1980; 
Hoffman et al. 1979; Mecham et al. 1983; Stern et al.1984; 
Yamamoto et al. 2020).
First reported in 1973, methioninase was initially isolated 
from Clostridium sporogenes and successfully inhibited the 
growth of Walker carcinosarcoma 256 implanted in male 
Wistar rats (Kreis and Hession 1973). Recently, with the 
use of patient-derived orthotopic xenograft (PDOX) mouse 
models of cancer, Kawaguchi et al. (2018) demonstrated 
that pancreatic cancer and melanoma exhibited methionine 
dependency. It was demonstrated that mice treated with 
recombinant methioninase exhibited a reduced tumour vol-
ume in both pancreatic (694 vs 201  mm2) and melanoma 
(3755 vs 858  mm2) cancer models (Kawaguchi et al. 2018). 
This work proposed that the recombinant methioninase 
decreased serum methionine levels, which in turn resulted 
in an inadequate methionine supply to the tumours, leading 
to a reduction in tumour volume.
Following the success of methioninase in preclinical 
models, studies have highlighted the potential of both intra-
venous and oral recombinant methioninase in human clinical 
trials. In a phase 1 clinical trial assessing metastatic breast 
cancer patients, plasma methionine levels decreased signifi-
cantly when administered with 20,000 units of recombinant 
methioninase (Tan et al. 1996). However, this trial did not 
assess anti-tumour activity. More recently, Han et al. (2020) 
investigated the use of oral recombinant methioninase as a 
supplement in advanced cancers. This study demonstrated 
an approximate 70% decrease in prostate-specific antigen in 
a patient with bone-metastatic prostate cancer following a 
twice daily dose of 250 units of methioninase over a 3-month 
period. Furthermore, the patient’s haemoglobin increased 
from 7.4 to 8.7 g/dl during the trial, suggesting increased 
bone functionality following treatment. Whilst the Han et al. 
(2020) study has demonstrated a potentially safe and effec-
tive treatment to reduce circulating methionine, double blind 
clinical trials are needed to assess efficacy regarding patient 
survival.
Taken together, the data from these studies supports the 
enzymatic depletion of AAs as a successful cancer therapy. 
Although this review focusses on the enzymes with the wid-
est clinical support, there are whole families of enzymes that 
have yet to be explored. However, whilst there is promise in 
these therapies many patients experience a hypersensitivity 
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reaction to the infused protein which limits the treatments 
use (Battistel et al. 2020; Zarei et al. 2019), highlighting a 
need for orally available treatments (Han et al. 2020). This 
also leaves opportunities for other mechanisms of AA deple-
tion, such as dietary restriction. The dietary restriction of 
phenylalanine and branched chain amino acids (BCAAs) are 
already performed in the clinical setting of phenylketonuria 
and maple syrup urine disease, respectively (Blackburn et al. 
2017).
Nutritional restriction of amino acids
Otto Warburg first noted changes in the metabolism of glu-
cose within malignant cells in order to support rapid cell 
proliferation, growth and survival (Warburg 1956). Regard-
less of oxygen status, malignant cells often produce energy 
by glycolysis followed by lactic acid fermentation (Fig. 1; 
Li et al. 2015). This altered metabolism has been exploited 
clinically through the use of fluorodeoxyglucose positron 
emission tomography, enabling the detection of malignant 
tumours (Hsu and Sabatini 2008). Due to the high rate of 
glucose consumption by malignant cells, glucose deprivation 
is an attractive therapeutic avenue in many cancers. Numer-
ous studies have demonstrated significantly lower glucose 
concentrations in malignant cells compared to correspond-
ing non-malignant tissues (Rocha et al. 2015; Urasaki et al. 
2012; Ziebart et al. 2011), with average reductions of up to 
46% reported in lung tumours (Rocha et al. 2015).
Malignant cells can even adapt to glucose poor condi-
tions by adopting alternative metabolic pathways to support 
growth. It has been demonstrated in conditions of glucose 
deprivation, malignant cells can synthesise glucose de novo 
from non-carbohydrate sources (gluconeogenesis) (Gras-
mann et al. 2019). Hodakoski et al. (2019) identified that 
the catabolism of alanine by alanine aminotransferase 2 
(ALT2) to pyruvate, was critical for the survival of non-
small cell lung carcinoma (NSCLC) cells during glucose 
starvation. After knockdown of ALT2, cells were signifi-
cantly more sensitive to glucose withdrawal compared to 
wildtype cells, which were rescued when supplemented with 
pyruvate. Increased ALT2 expression has also been reported 
in human breast cancer and demonstrated a positive correla-
tion with tumour grade and proliferation (Cao et al. 2017). 
This research highlights the significant role of glucogenic 
AAs to feed gluconeogenesis in glucose deprived environ-
ments (Cao et al. 2017; Hodakoski et al. 2019). However, 
as 19 out of 22 AAs are considered glucogenic, restriction 
does not seem practical in a clinical setting.
A common example of dietary cancer therapy is the 
ketogenic diet, providing a fat-rich, low carbohydrate 
diet. The rationale is to reduce circulating glucose levels 
and induce ketosis. This promotes energy starvation in 
malignant cells that are unable to utilise ketone bodies, 
whilst non-malignant cells adapt (Klement 2017; Weber 
et al. 2018). The ketogenic diet has been demonstrated to 
decrease cancer progression within mouse models of meta-
static cancer, slowing tumour growth and increasing mean 
survival by 56.7% (31.2 vs 48.9 days) (Poff et al. 2013). 
Zhou et al. (2007) compared a standard diet to a ketogenic 
diet where the major difference between these diets was 
the ketogenic ratio of 4:1 (fat: carbohydrate and protein) 
when following the ketogenic diet. Intracerebral tumour 
growth of both the CT-2A and U87-MG tumours were 
reduced by approximately 65% and 35%, respectively. This 
was associated with improved survival in the ketogenic 
diet group when compared to control mice. Further to 
these studies, Rieger et al. (2014) used mouse models to 
observe the effects of a ketogenic diet in combination with 
bevacizumab, a drug designed to block vascular endothe-
lial growth factor (Byrne et al. 2005). The combination 
of both bevacizumab and a ketogenic diet resulted in a 
42% reduction in tumour volume when compared to mice 
receiving bevacizumab alone (13.8  mm3 vs 23.9  mm3), 
which was reflected in an increased survival. Despite 
the promising preclinical data, human studies have not 
shown consistent clinical improvement. However, many 
human studies are limited by factors including low patient 
numbers, poor adherence, lack of randomisation and the 
absence of a control group. These factors are controlled 
in preclinical studies utilising animal models, which may 
be the reason that preclinical success was not replicated 
in the human trials.
Increasing evidence has highlighted that BCAAs, leucine, 
isoleucine and valine, are required for malignant growth and 
act as a source of energy in many cancers (Ananieva and 
Wilkinson 2018). Recent evidence has demonstrated that 
the key enzymes in BCAA metabolism: the branched chain 
aminotransferase (BCAT) and the branched chain keto acid 
dehydrogenase complex are overexpressed in many can-
cers and correlate with poorer survival, chemotherapeutic 
resistance, and enhanced cancer cell proliferation, migra-
tion and invasion (Conway et al. 2016; Hattori et al. 2017; 
Mayers et al. 2016; Tönjes et al. 2013; Zheng et al. 2016). 
Increased expression of BCAT and increased BCAA uptake 
was observed in mouse NSCLC tumours, in which leucine 
uptake was over threefold higher than control lung tissue. 
In NSCLC tumours, leucine uptake contributed to DNA 
and NEAA synthesis, important for tumour growth, while 
pancreatic ductal adenocarcinoma (PDAC) tumours demon-
strated decreased BCAA uptake and little utilisation (May-
ers et al. 2016). In contrast, Dey et al. (2017) demonstrated 
that BCAT2 overexpression in PDAC cells positively cor-
related with the aggressive growth in PDAC tumours driven 
by chr18q21 chromosomal deletion, suggesting (conversely) 
PDAC tumours are dependent on BCAAs.
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It is apparent that BCAA metabolism in cancer is com-
plex. The long-term dietary restriction of all 3 BCAAs is 
required for maple syrup urine disease treatment and has 
demonstrated a successful clinical outcome for an other-
wise fatal disease (Blackburn et al. 2017). Utilising dietary 
BCAA restriction in cancer therapy could inhibit the varying 
carcinogenic pathways that require BCAAs or its metabo-
lites. However, current clinical data assessing dietary inter-
ventions targeting cancer are lacking, despite promising pre-
clinical data. For example, Komninou et al. (2006) assessed 
the dietary restriction of methionine on an azoxymethane-
induced colon carcinogenesis rat model. The formation of 
preneoplastic aberrant crypt foci in the colon was reduced in 
rats fed on a methionine restricted diet, with a 12% reduction 
in colonic cell proliferation compared to controls. However, 
dietary restriction is often complicated due to the complex 
AA content of food. The isolation of a single AA whilst 
maintaining a varied and nutritious diet is difficult but is 
possible when following a diet of medical origin. However, 
it may be more clinically manageable to instead target the 
metabolism of specific AAs, rather than restricting them.
Enzymatic inhibition of amino acid 
metabolism
A number of pharmacological inhibitors have been exten-
sively researched to inhibit the function of key enzymes 
involved in AA metabolism, thus disrupting cancer pro-
gression. The BCAT enzyme has been identified in having 
a central role in the pathogenesis of a number of cancers 
(Hattori et al. 2017; Mayers et al. 2016; Tönjes et al. 2013), 
with knockdown of the BCAT gene demonstrating reduced 
proliferation of cancer cells both in vitro and in vivo (Hattori 
et al. 2017; Tönjes et al. 2013). The medication gabapentin, 
originally designed as a gamma‐aminobutyric acid‐mimetic, 
has demonstrated both anticonvulsive and analgesic effects. 
Although the mechanism of gabapentin remains unclear, its 
main molecular target involves the inhibition of voltage-
gated calcium channels at dorsal root ganglion neurons, 
which contributes to its pain attenuating effects (Kukkar 
et al. 2013). However, evidence has described gabapentin as 
an inhibitor of BCAT1. Structural analysis has demonstrated 
gabapentin acts as an analogue of leucine and can competi-
tively inhibit the transaminase activity of BCAT1 (Goto 
et al. 2005). In vitro studies have demonstrated that inhi-
bition of BCAT1 by gabapentin dose-dependently disrupts 
clonogenic growth in chronic myeloid leukaemic cells and 
promotes intracellular BCAA accumulation (Hattori et al. 
2017). Supporting this, following treatment with gabapentin 
levels of valine, leucine and isoleucine increased by factors 
of 1.83, 2.18 and 2.32, respectively, in gliomas that harbour 
wildtype isocitrate dehydrogenase 1 (Tönjes et al. 2013). 
This reduced BCAT activity was associated with reduced 
glutamate release and led to reduced proliferation and inva-
siveness in vitro (Tönjes et al. 2013).
Not all studies have confirmed that the anti-proliferative 
effects of gabapentin on tumour cells are dependent of 
BCAT1 inhibition. Grankvist et al. (2018) demonstrated 
that at 10 mM, gabapentin significantly reduced the growth 
of colon cancer cells by approximately 50% at 96 h, despite 
little BCAT1 expression and BCAT2 as the major isoform. 
Additionally, the cells were supplemented with branched 
chain keto acids which failed to recover cell growth in the 
presence of gabapentin, demonstrating that inhibition of 
cancer cell growth was not due to inhibition of BCAT2. The 
mechanism by which gabapentin suppresses cancer cell 
growth in these cells remains unclear. However, the diverse 
anti-cancer activity of gabapentin highlights it as a candidate 
for treatment against cancers with different metabolic phe-
notypes. For example, malignancies that lack BCAT activ-
ity and have little dependency on BCAAs or those that rely 
on BCAT2 activity rather than BCAT1 (Dey et al. 2017; 
Grankvist et al. 2018; Mayers et al. 2016).
In the 1950s, a dependence on an abundant supply of 
exogenous glutamine was noted in mammalian cell lines 
(Eagle 1955). Glutamine metabolism contributes to a num-
ber of diverse roles which support the ability of malignant 
cells to meet increased energy demands and continuously 
grow. This includes energy generation, cell proliferation, 
maintaining redox homeostasis and the synthesis of NEAAs, 
fatty acids and nucleotides (Fig. 2; Martinez-Outschoorn 
et al. 2017). However, recent studies have demonstrated 
that glutamine requirements are heterogeneous amongst 
different cell lines and that the tissue of origin, genetics and 
the tumour microenvironment all impact the utilisation of 
glutamine within the cancer cell (Cluntun et al. 2017). As 
a NEAA, glutamine is synthesised de novo by the enzyme 
glutamine synthetase (Tardito et al. 2015). However, some 
malignancies rely on an exogenous supply of glutamine due 
to a low expression of glutamine synthetase (Cluntun et al. 
2017). Therefore, in the absence or inhibition of glutami-
nase, malignancies which rely on energy from an exogenous 
supply of glutamine will be unable to utilise nutrients from 
this source.
There are a number of approaches to target glutamine 
metabolism including blocking cellular uptake of glu-
tamine, depletion of glutamine in the blood and inhibition 
of enzymes involved in glutamine synthesis and catabolism, 
all of which provide potential avenues for cancer therapy 
(Lukey et al. 2013; Martinez-Outschoorn et al. 2017). Tar-
geting glutaminase function utilising small molecules or 
gene knockdown approaches has produced promising pre-
clinical results in many malignancies such as NSCLC and B 
cell lymphoma (Le et al. 2012; Van den Heuvel et al. 2012). 
Glutaminase inhibitors have demonstrated success in both 
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preclinical and clinical studies. Telaglenastat (CB-839) is 
a potent and selective inhibitor of both splice variants of 
glutaminase, which has exhibited antiproliferative effects on 
triple negative breast cancer cell lines and xenograft mod-
els (Gross et al. 2014). In a patient-derived triple negative 
breast cancer xenograft, Gross et al. (2014) demonstrated a 
61% inhibition of tumour growth with telaglenastat treat-
ment alone. Furthermore, treatment with a combination of 
telaglenastat and paclitaxel demonstrated a 100% tumour 
inhibition relative to controls.
Phase 1 clinical trials have demonstrated the success of 
telaglenastat as a well-tolerated monotherapy in patients 
with multiple myeloma and lymphoma through the suc-
cessful inhibition of glutaminase in tumours (Vogl et al. 
2015). Vogl et al. (2015) also highlighted the success of 
telaglenastat in combination with pomalidomide/ dexa-
methasone, supporting the clinical use of telaglenastat for 
relapsed multiple myeloma. Further phase 1 studies also 
demonstrated the success of telaglenastat as a monotherapy 
in addition to studying combinations with other drugs such 
as everolimus in patients with renal cell carcinoma (Meric-
Bernstam et al. 2016). As a result of the success demon-
strated in phase 1 clinical trials, the work has progressed 
into phase 2 with one active phase 2 trial comparing tela-
glenastat in combination with everolimus to a placebo with 
everolimus in advanced or metastatic renal cell carcinoma. 
The randomised, double-blind, placebo-controlled phase 2 
trial is approaching completion (National Institute of Health 
2017). However, initial results from the trial are promising, 
with a median progression-free survival of 3.8 months when 
Fig. 2  The role of glutamine in cancer. Glutamine enables rap-
idly proliferating cells to meet increased energy demands in addi-
tion to its utilisation in protein synthesis. Glutamine enters the cell 
via the amino acid transporter SLC1A5 and is converted to gluta-
mate in the mitochondria via a deamination reaction catalysed by 
GLS. Glutamate is further converted to the TCA cycle intermediate 
α-ketoglutarate. α-ketoglutarate is a critical metabolite involved in 
both ATP production and replenishing TCA cycle intermediates (ana-
plerosis). Cytosolic glutamate is critical for maintaining redox home-
ostasis through the production of GSH which protects against oxida-
tive stress. Glutamine efflux via the SLC7A5 amino acid transporter 
allows leucine to enter the cell and activate mTORC1-mediated cell 
growth. Abbreviations: AST aspartate transaminase; ATP adenosine 
triphosphate; GDH glutamate dehydrogenase; GLS glutaminase; GSH 
S-glutathione; mTORC1 mammalian target of rapamycin complex 1; 
NADP ± nicotinamide adenine dinucleotide phosphate; RAS rat sar-
coma GTPase; SLC1A5 solute carrier family 1 member 5; SLC7A5 
solute carrier family 7 member 5; TCA tricarboxylic acid. Adapted 
in Biorender from Choi and Park (2018); Hensley et al. (2013); Mar-
tinez-Outschoorn et al. (2017)
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patients were treated with telaglenastat and everolimus, 
compared to 1.9 months for those who received the placebo 
and everolimus (Motzer et al. 2019). This promising initial 
data, along with the progression of other studies to phase 2 
clinical trials, provides support for the use of telaglenastat 
as a successful glutaminase inhibitor.
Conclusion
The extensive mutational heterogeneity of cancer highlights 
a growing need for personalised medicine. Therapies cur-
rently exist to target the many pathways associated with 
tumour progression. Yet many patients suffer due to the 
toxicity of these treatments, in addition to cancer cell adap-
tations which results in chemoresistance. Research needs 
to identify novel therapeutic avenues to tackle the resistant 
forms of these cancers or provide a less aggressive alterna-
tive to current therapies in patients not deemed fit to treat. 
Amino acids are required for a number of vital processes 
and many malignant cells exhibit genetic abnormalities that 
compromise their ability to obtain or utilise an adequate sup-
ply of the AAs required for tumorigenesis. Nutrient restric-
tion, enzymatic depletion and enzymatic inhibition of AA 
metabolism have all demonstrated success in preclinical 
and clinical models, supporting these therapies as viable 
strategies for cancer treatment (Table 1). These alterna-
tive approaches have the potential to revolutionise standard 
clinical practice and could transform relapse and reoccur-
rence statistics for many cancers. However, initial promising 
results need to be supported by double-blind clinical trials. 
The research summarised in this review promises success 
in the underlying principle of AA restriction as an effective 
non-genotoxic therapy, that can be utilised as both a mono-
therapy or combination therapy.
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